No Data
The Nikkei average is up about 290 yen, and after a round of Buy, it is being pushed down by Sell waiting for a rebound = 24 days before the session.
On the 24th at around 10 AM, the Nikkei average stock price is trading at around 35,160 yen, up about 290 yen from the previous day. At 9:08 AM, it reached 35,287 yen 95 sen, up 419 yen 32 sen. In the US market on the 23rd local time, following President Trump's indication that tariffs on China would significantly decrease from 145%, both the NY Dow and Nasdaq continued to rise. Additionally, it was reported that Treasury Secretary Yellen expressed that there would be no specific currency targets in the Japan-US negotiations regarding tariffs.
List of stocks that have broken through the clouds (weekly chart) (Part 1)
○ List of stocks above the clouds in the market Code Stock Name Closing Price Leading Span A Leading Span B Main Board <1301> Kiyokawa 4280 4116.25 4000 <1333> Maruha Nichiro 3232 3092.5 2918.5 <1815> Tekken 2526 2463 2442.5 <1852> Asanuma Corporation 7546 90.57 39 <1879> Shin Nippon Construction 1583 1529.75 1407.5
Asuka Pharmaceutical's shareholding with Nippon Active has increased to 19.43%.
It has been revealed that the shareholding ratio of Asuka Pharmaceutical Co., Ltd. <4886.T> by Nippon Active Value Fund (Nippon Active) and its co-holders has increased. According to the large shareholding change report submitted by Nippon Active after the market close on the 5th, the shareholding ratio with co-holders rose from 17.94% in the previous submission to 19.43%. The purpose of the shareholding is stated to be for investment and to provide management advice to the management team, as well as to engage in significant proposal activities as appropriate.
ASKA Pharmaceutical Holdings To Go Ex-Dividend On March 28th, 2025 With 25 JPY Dividend Per Share
March 27th (Japan Standard Time) - $ASKA Pharmaceutical Holdings(4886.JP)$ is trading ex-dividend on March 28th, 2025.Shareholders of record on March 31st, 2025 will receive 25 JPY dividend per share.
Sasmid's business expansion following the insomnia treatment app is proceeding smoothly.
Sasmid <4263> has set the Task Center to "continue to provide sustainable Veterinary Services to society through the utilization of ICT," and is a venture company in the research and development stage that develops digital therapeutics (Digital Therapeutics, hereinafter referred to as DTx), which is gaining attention as the third treatment method following Pharmaceuticals and Medical Devices. The company is engaged in the DTx product business that develops therapeutic applications and the DTx platform business that supports clinical trial efficiency for pharmaceutical companies.
List of conversion stocks [List of parabolic signal conversion stocks]
○ List of Stocks for Buy Change Market Code Stock Name Closing Price SAR Tokyo Main Board <1812> Kashima 3125 <1820> Nishimatsu Construction 50264816 <1946> Toenek 1011957 <1950> Japan Electric Utility 21992096 <1951> Exeo Group 17691711 <2121> MIXI 34203290 <2154> Open UP 18681756 <25
